TrueBinding, Inc. has announced that the FDA has cleared its Investigational New Drug (IND) application for TB006, a Biologic IgG4 antibody designed to neutralize Galectin-3, for potential disease modification in Parkinson’s Disease.
Novel Approach to Parkinson's Treatment
TB006 represents a first-in-class therapy that leverages antibody selectivity to target Galectin-3, a protein implicated in the pathogenesis of Parkinson's Disease. Alan K. Jacobs, M.D., FAAN, Chief Medical Officer of TrueBinding, stated, "FDA IND approval for TB006 is a major achievement for TrueBinding and a significant potential advancement for the treatment of Parkinson’s Disease worldwide," highlighting the potential of this novel treatment option for patients lacking disease-modifying therapies.
Mechanism of Action
Administered via monthly intravenous infusion, TB006 is designed to neutralize Galectin-3, potentially enabling the dissociation of neurotoxic oligomers, including alpha-synuclein. This action aims to reduce the activation of pro-inflammatory microglia and the release of associated cytokines, while also providing reparative impact upon intracellular lysosomes.
Phase 2A Trial Details
The upcoming multi-center, placebo-controlled, Phase 2A trial in the U.S. will evaluate the safety and efficacy of TB006 in patients with early to mild Parkinson’s Disease. The trial will enroll adults aged 50 to 80 years with confirmed Hoehn and Yahr grade 1 or 2 Parkinson’s Disease, diagnosed within five years, and who are either not on Parkinson’s Disease medications or only using immediate-release Levodopa-containing therapy. The study aims to enroll 62 patients, with an estimated primary completion date in Q1 2026 (NCT number not provided in source).
Parkinson's Disease: A Growing Concern
Parkinson’s disease is a progressive neurodegenerative disorder affecting dopamine-producing cells. Nearly one million people in the U.S. and 10 million people worldwide are living with PD, with approximately 90,000 new cases diagnosed annually in the U.S. As the second most common neurodegenerative condition after Alzheimer’s, the prevalence of Parkinson’s is expected to increase substantially due to the aging population.
About TB006
TB006 is a humanized monoclonal antibody that preclinical data suggests can improve cognition and functioning in patients with Alzheimer’s and Parkinson’s Disease. Preclinical studies have indicated that Galectin-3 promotes the aggregation of Aβ and pTau proteins. In Alzheimer’s Disease in vivo models, TB006 demonstrated promising capabilities in reducing the aggregation of Aβ/Tau proteins and neuroinflammation, leading to improved cognitive performance. A Phase 1b/2 proof-of-concept trial in mild to severe Alzheimer’s patients showed a positive trend toward improvements in cognition and functioning. TB006 has also been evaluated in a Phase 2 open-label extension trial in patients with Alzheimer’s Disease and has been allowed by the FDA for conditional use through an Expanded Access Program. Clinical trials have shown that TB006 was well tolerated with a favorable safety profile.
